Research lines of Chronic Obstructive Pulmonary Disease

Reading time: 1 min

There have been changes in the therapeutic management of COPD over the last 10 years, with the arrival of new inhaled drugs of the long-acting beta-adrenergic receptor agonists (LABA), long-acting muscarinic receptor antagonists (LAMA) groups and inhaled corticosteroids (ICS).

This new therapeutic arsenal provides a wider range of options that will lead to improvement in the symptoms, tolerance to exertion, and the quality of life. However, there are clinical trials currently being conducted all over the world that include thousands of patients and will analyse the efficacy of the new drugs that could be capable of slowing down the progression of the disease.

In this sense, the potential role of the emerging drugs, such as the new anti-inflammatory agents (mitogen activated protein (MAP) kinase inhibitor, losmapimod), and monoclonal antibodies (canakinumab, benralizumab, mepolizumab), is an important aspect being looked at with great enthusiasm. In fact, it is interesting to observe that the future pharmacological treatment options for COPD could include new intervention strategies, as well as the new inhaled therapies that have been at the heart of its management for the last 20 years.

Substantiated information by:

Nestor Soler Porcar
Núria Seijas Babot

Published: 20 February 2018
Updated: 20 February 2018

The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.


Receive the latest updates related to this content.

Thank you for subscribing!

If this is the first time you subscribe you will receive a confirmation email, check your inbox

An error occurred and we were unable to send your data, please try again later.